Copy
CANCER CLINICAL TRIALS NEWSLETTER

This is a 2-phase study for individuals diagnosed with an advanced solid tumor. Phase 1 is a dose escalation phase with multiple cohorts. Cohort A will receive ALKS4230 weekly via IV infusion, while Cohort B will receive it every 3 weeks with a starting dose of .3mg, and increasing from there. The primary endpoint for phase 1 of this study is The incidence and severity of treatment-emergent AEs.

Phase 2 is an expansion cohort for individuals with lymphoma, head and neck, pancreatic, or lung cancer. The primary endpoint for this phase is overall response rate.
(ALKS4230-001, IRB 2019-1378)

M19-700
IRB 2020-0121
A Phase 1b Study of Venetoclax in Combination with Pembrolizumab in Subjects with Previously Untreated NSCLC Whose Tumors have High PD-L1 Expression
R2810-ONC-1788
IRB 2019-0734
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo After Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included

It takes only seconds to get the new app. On your phone, simply go to https://ctra.highenroll.org. Add the app to your home screen for quick and easy use.  Please delete all other prior versions of the app. 

If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, dlsteen@highenroll.org or Ginger Conway @859-992-5339, gaconway@highenroll.org.

 

 Thanks,

Dylan and Ginger

https://uc.us20.list-manage.com/track/open.php?u=6e0c6353f4d0cff892fa85067&id=17c04815d2&e=e50cd33d0c

Understanding pancreatic cancer, one gene at a time

UC researcher investigates various mutations in pancreatic cancer to find targeted ways to treat it. He’s creating models to help study variations of the disease and find the best possible treatment for each mutation involved in its development.
Click Here to Visit the UC Newsroom
State of the Science Summit: Ovarian Cancer 

Thursday, Sep. 3, 2020  | 5:00pm–9:00pm
Renaissance Cincinnati Downtown Hotel 
36 E. 4th St. Cincinnati, OH 45202

Keynote Speaker:
Thomas Herzog, MD
University of Cincinnati Cancer Center

Ritu Salani, MD
UCLA


For more information or questions, email kelly.hummel@uc.edu, or call 513-558-2030.

View Flyer as PDF
Division of Hematology Oncology Grand Rounds Schedule
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
CANCER CLINICAL TRIALS NEWSLETTER
Questions?  Please call us at 513-584-7698, or email us!
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu
Copyright © 2019, All rights reserved.

UC Cancer Institute Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
natalie.ciulla@uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA